Digestery
Longevity supplements › Metformin and Aging › Studies

Pooled review (meta-analysis)

Pooled review: in diabetes, metformin was linked to lower liver cancer risk

Li and colleagues · Clinics and research in hepatology and gastroenterology · 2022

Original title: Impact of metformin use on risk and mortality of hepatocellular carcinoma in diabetes mellitus.

Under review. A person has not yet checked this summary against the paper. It is written from the PubMed abstract. Until a person checks it, search engines are asked not to list this page.

What the study found

Points to benefit

Metformin use was linked to lower liver cancer risk (OR/RR = 0.59, 95% CI 0.51-0.68) and lower all-cause death in those with liver cancer (HR = 0.74, 95% CI 0.66-0.83).

The study at a glance

Type of study
Pooled review (meta-analysis)
Who or what was studied
People with diabetes, with and without metformin, studied for liver cancer
What was tested
Metformin use vs non-use in diabetes, for liver cancer risk and death from liver cancer
What it measured
The question itself: aging, frailty and death in people without diabetes
Who has a stake
No stake declared
No competing interests declared.
Journal
Clinics and research in hepatology and gastroenterology, 2022
Source
PubMed record 34332136. This page is based on the abstract only.

How much this study counts

  • ✓Pools the results of many studies.
  • •A pooled review is only as strong as the studies it pools.
  • ✓Measured the question itself: aging, frailty and death in people without diabetes.
  • ✓No competing interests declared.
  • •Summarized from the PubMed abstract only. The full paper may hold details the abstract leaves out.

✓ Strength– Limit• Note

These points come from fixed rules about the type of study, its size and length, what it measured, and who has a stake. Every study on Digestery gets the same rules.

Where this study sits

This paper is not on the ladder. It is a pooled review (meta-analysis), and reviews and opinion pieces discuss studies that are already counted on the steps below.

↑ Stronger evidence

  1. Trials in people: aging and age-related disease

    1

    1 benefit

  2. Trials in people: other measures

    3

    2 no difference, 1 harm

  3. Trials in people: lab tests or safety

    6

    2 benefit, 2 mixed, 2 no difference

  4. Population studies

    8

    6 benefit, 2 no difference

  5. Blood levels and genes

    0

    None among the papers we read.

  6. Animals

    3

    2 benefit, 1 harm

↓ Weaker evidence

  • Points to benefit
  • Mixed
  • No difference
  • No direction
  • Points to harm

How it fits with the other research

The short answer to “Does metformin slow aging in people without diabetes?”

Not shown in people without diabetes.

Confidence: low. Based on 26 on-topic papers.

Read the full answer
  • Part of the finding “Fewer deaths seen only in people with diabetes”.
  • Summed up in “What reviews found”: Pooled studies of people with diabetes; the abstract does not give the count. Metformin use was linked to lower liver cancer risk (OR/RR = 0.59) and fewer deaths among people with liver cancer (HR = 0.74). Study results varied widely.

Other reviews on this question

See all 26 studies on this question

How this page was made

Label

First read of the abstract
Claude Sonnet
Independent second read
Claude Haiku
Differences settled
The two reads agreed on every checked field. Claude Opus 5.5.
Headline
Claude Sonnet, from the checked study record. A script checked its numbers and wording.
Numbers
Checked against the abstract by a script
“How much this study counts”
Fixed rules, the same for every study
Source check by a person
Not yet. Required before search engines may list this page.

Spot an error? Email a flag with a link to your source, or use the form on the question page.